Intraday Trading Highlights
On the day of this record, Venus Remedies opened with a gap up of 4.94%, signalling strong initial demand. The stock experienced considerable volatility, with an intraday price range spanning from Rs.740.3 to the peak of Rs.808.5, representing an 18.37% weighted average price volatility. Despite a day’s closing change of -0.82%, the stock outperformed its sector by 1.28%, underscoring its relative strength within the Pharmaceuticals & Biotechnology space.
Recent Price Momentum and Moving Averages
The stock has recorded gains over the last four consecutive trading sessions, accumulating a return of 12.77% during this period. Venus Remedies is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a robust upward trend across multiple timeframes.
Comparative Performance Versus Benchmarks
Venus Remedies’ performance over various time horizons has been notable when compared to the Sensex benchmark. Over the past week, the stock appreciated by 5.30%, while the Sensex declined by 0.67%. The one-month return stands at 71.44%, significantly outpacing the Sensex’s 2.03% gain. Over three months, the stock’s return of 64.50% contrasts with the Sensex’s 5.49%. The one-year performance is particularly striking, with Venus Remedies delivering 132.49% returns against the Sensex’s 5.18%. Year-to-date, the stock has recorded a 141.16% return, compared to the Sensex’s 8.97%.
Long-Term Growth Trajectory
Examining longer-term data, Venus Remedies has generated a 282.20% return over three years, substantially exceeding the Sensex’s 35.44% for the same period. Over five years, the stock’s return of 464.85% dwarfs the Sensex’s 88.89%. Even over a decade, Venus Remedies has delivered 470.57% returns, compared to the Sensex’s 232.12%, highlighting its sustained growth and value creation over time.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Financial Performance and Profitability Metrics
Venus Remedies has demonstrated strong financial results in recent quarters. The company reported a net profit growth of 473.5% in the September 2025 quarter, continuing a positive trend with four consecutive quarters of profit declarations. The profit after tax (PAT) for the latest six months stands at Rs.29.73 crores, reflecting a growth of 528.54%. Profit before tax excluding other income (PBT less OI) for the quarter reached Rs.24.78 crores, showing a substantial increase of 2073.68%.
Return on Capital and Valuation Metrics
The company’s return on capital employed (ROCE) for the half-year period is recorded at 13.99%, the highest in recent assessments. Return on equity (ROE) is at 10.5%, accompanied by a price-to-book value ratio of 1.7, indicating an attractive valuation relative to its peers. The stock’s price-to-earnings-to-growth (PEG) ratio stands at 0.1, reflecting the relationship between its price, earnings, and growth rate.
Debt Position and Market Capitalisation
Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which suggests a conservative capital structure with minimal reliance on debt financing. The company’s market capitalisation grade is rated at 4, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector.
Market Performance Relative to Peers
Over the past year, Venus Remedies has generated returns of 133.76%, while its profits have risen by 183%. The stock has outperformed the BSE500 index over the last three years, one year, and three months, underscoring its consistent market strength and resilience.
Want to dive deeper on Venus Remedies ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Investor Composition and Market Considerations
Despite the company’s size and market presence, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund participation may reflect a cautious stance or valuation considerations at prevailing price levels. Such a scenario highlights the importance of ongoing market evaluation and the diverse perspectives within institutional investment circles.
Summary of the Milestone Achievement
Venus Remedies’ attainment of an all-time high price of Rs.808.5 represents a culmination of sustained financial growth, strong profitability metrics, and consistent market performance. The stock’s ability to maintain trading levels above key moving averages and its outperformance relative to sector and benchmark indices reinforce the significance of this milestone. The company’s conservative debt profile and attractive valuation metrics further contextualise its market position.
Conclusion
The record high reached by Venus Remedies is a testament to its enduring presence in the Pharmaceuticals & Biotechnology sector. The company’s financial results, long-term returns, and market behaviour collectively illustrate a trajectory of growth and resilience. This achievement marks a notable chapter in Venus Remedies’ market journey, reflecting its capacity to navigate competitive dynamics and deliver value over time.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
